The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma

Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unknown. Here we report that levels of fatty acid elongase 6 (ELOVL6) were lower in MM ce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Lipchick, Brittany C., Utley, Adam, Han, Zhannan, Moparthy, Sudha, Yun, Dong Hyun, Bianchi-Smiraglia, Anna, Wolff, David W., Fink, Emily, Liu, Liang, Furdui, Cristina M., Lee, Jingyun, Lee, Kelvin P., Nikiforov, Mikhail A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045499/
https://ncbi.nlm.nih.gov/pubmed/33821992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002578
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados